Viveve Medical, Inc. (NASDAQ:VIVE) has been given a consensus recommendation of “Buy” by the six analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $10.40.
Several analysts recently weighed in on the company. Mizuho assumed coverage on Viveve Medical in a research note on Thursday, November 16th. They set a “buy” rating and a $10.00 target price for the company. Cowen set a $11.00 target price on Viveve Medical and gave the company a “buy” rating in a research note on Monday, October 23rd. Finally, ValuEngine downgraded Viveve Medical from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th.
Viveve Medical (NASDAQ VIVE) traded down $0.06 on Monday, hitting $4.90. The stock had a trading volume of 64,713 shares, compared to its average volume of 180,997. Viveve Medical has a 52 week low of $3.75 and a 52 week high of $11.16. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72.
A number of large investors have recently made changes to their positions in the stock. Rhumbline Advisers bought a new stake in Viveve Medical during the 2nd quarter valued at approximately $110,000. JPMorgan Chase & Co. bought a new stake in Viveve Medical during the 2nd quarter valued at approximately $151,000. Virtu KCG Holdings LLC bought a new stake in Viveve Medical during the 2nd quarter valued at approximately $169,000. Granahan Investment Management Inc. MA boosted its stake in Viveve Medical by 32.6% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock valued at $535,000 after purchasing an additional 25,097 shares during the period. Finally, Schwab Charles Investment Management Inc. bought a new stake in Viveve Medical during the 2nd quarter valued at approximately $189,000. Hedge funds and other institutional investors own 67.02% of the company’s stock.
WARNING: “Viveve Medical, Inc. (VIVE) Receives Consensus Recommendation of “Buy” from Analysts” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/12/12/viveve-medical-inc-vive-receives-consensus-recommendation-of-buy-from-analysts.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.